$NNVC: New Approach to Treating Viral Infections #nanoviricides #viraltherapeutics buff.ly/OgH9tJy

$GMGI turned in a record quarter #AI #igaming buff.ly/spGAgpA

$TSEM: Investors Begin to See Tower Semiconductor as a AI Data Center Play buff.ly/rOnapo1 by Lisa Thompson

$RANI Adds Two New Board Members #biologics #robotics buff.ly/78evQLW

$RADX: Model Updates for 1Q:26 Cash Flows #Radiopharmaceuticals #NuclearMedicine buff.ly/y8DMPMc

$CPSS: Consumer Portfolio Services 3Q25 Earnings Review – EPS Miss on Higher Interest Expense; Operating Leverage Increasingly Shining Through buff.ly/2PFszQ6

At OTC Nordic Investor Day 2025, panelists from OTC Markets Group, SEB, @Borenius, & @NanoCAP discussed strategies for Nordic companies accessing U.S. capital markets. Replay available now: buff.ly/eY3qExP #NordicInvesting #CapitalMarkets #InvestorRelations

$FBLG: Fibroblast Therapy Ready to Enter the Clinic #CellularTherapy #Fibroblasts buff.ly/o5ZEcXc

Recent launch of College Influencer Tour as $DBGI looks to expand NIL college apparel model to additional schools #ModernRetailTech #EcommerceInnovation buff.ly/2JofLn2

$NIVF: Transformational Reverse Merger; Pro Forma NPV of ~$7 Billion #HealthTechInvesting #FertilityTech buff.ly/MJDNG13

$GMGI: Multiple upcoming potential growth drivers, including FIFA World Cup games #igaming #softwaresolutions buff.ly/VUYq7XH

$DTWX: Using Pufferfish Toxin to Treat Neuropathy #PainTherapeutics #Biotech buff.ly/zDd83ic

$VIOT VIOMI Global: Xiaomi relationship fuels exceptional first-half performance. Increasing our target valuation to $5.00/ADS buff.ly/mFQ4Vno

$ACHV: New Executive Appointments As Achieve Heads Towards Approval #biotech #nicotine buff.ly/afFc7gB

$HIT: Health In Tech Strong 3Q & Outlook, With New Solutions Recently Introduced, Others Being Developed buff.ly/kL27kEh

$VREOF: Vireo 3Q25 Earnings Review – GAAP EPS Miss, but Strength Beneath the Surface buff.ly/vFjFR97

$REVB Ready to Break Out #immunesystem #inflammation buff.ly/SaUKYZ0

$ETST Earth Science Tech, Inc.: F2Q26 Earnings Review – EPS as Expected; Growth Set to Ramp Up buff.ly/5TwF6uK

$EDSA: Charting Next Steps After Positive Phase 3 Results #biopharma #ARDS buff.ly/kaUVRmh

$MTVA: Early Efficacy Data for Phase 1 Obesity Trial in Dec 2025 #smallcaps #biopharma buff.ly/AfB8NVp